Absci Corporation will report Q2 2025 results on August 12, followed by a conference call at 4:30 p.m. ET.
Quiver AI Summary
Absci Corporation, a clinical-stage biopharmaceutical company, announced that it will report its second quarter 2025 business updates and financial results after market close on August 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss its developments and outlook, with the audio webcast available on its investor relations website. Absci utilizes generative design for drug discovery, combining AI models with synthetic biology to create innovative therapeutics. They are advancing their pipeline, which includes promising treatments like ABS-101 for inflammatory bowel disease and ABS-201 for hair regrowth. Absci is based in Vancouver, Washington, with additional facilities in New York City and Switzerland.
Potential Positives
- Absci Corporation is scheduled to report its second quarter 2025 business updates and financial results, which can positively influence investor confidence and stock performance.
- The planned webcast and conference call indicate a commitment to transparency and communication with investors, fostering trust and engagement.
- Absci's innovative Integrated Drug Creation™ platform leverages AI and synthetic biology, positioning the company at the forefront of drug discovery and potentially improving its competitive advantage in the biopharmaceutical industry.
- The advancement of Absci’s pipeline, including therapeutics for inflammatory bowel disease and hair regrowth, highlights the company’s ongoing commitment to significant therapeutic innovations with broad market potential.
Potential Negatives
- Absci has not provided any specific information regarding its financial performance or any potential issues that may have arisen in the second quarter of 2025, which could lead to investor concerns prior to the upcoming announcement.
- The scheduled conference call to discuss results indicates that the company may have important information to disclose, which could suggest that the current performance may not meet investor expectations or market standards.
- Absci's reliance on innovative technologies such as AI and synthetic biology may be seen as a risk if the market does not respond positively to their therapeutic candidates, raising concerns about the viability of their drug development approach.
FAQ
What is Absci Corporation's next financial report date?
Absci Corporation will report its financial results for the second quarter on August 12, 2025.
Where can I watch the Absci conference call?
The Absci conference call will be available on their investor relations website at investors.absci.com.
What innovative technologies does Absci use?
Absci employs generative design and AI models with a synthetic biology data engine to create therapeutics.
What are some key products in Absci’s pipeline?
Key products include ABS-101 for inflammatory bowel disease and ABS-201 for hair regrowth.
How can I contact Absci for investor inquiries?
You can contact Absci for investor inquiries at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ABSI Insider Trading Activity
$ABSI insiders have traded $ABSI stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ABSI stock by insiders over the last 6 months:
- ANDREAS BUSCH (Chief Innovation Officer) purchased 50,000 shares for an estimated $152,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ABSI Hedge Fund Activity
We have seen 76 institutional investors add shares of $ABSI stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 4,873,904 shares (+36.1%) to their portfolio in Q1 2025, for an estimated $12,233,499
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 2,307,698 shares (+inf%) to their portfolio in Q1 2025, for an estimated $5,792,321
- FRED ALGER MANAGEMENT, LLC removed 2,211,391 shares (-34.0%) from their portfolio in Q1 2025, for an estimated $5,550,591
- BANK OF AMERICA CORP /DE/ added 1,475,554 shares (+1673.0%) to their portfolio in Q1 2025, for an estimated $3,703,640
- UBS GROUP AG added 1,349,062 shares (+188.9%) to their portfolio in Q1 2025, for an estimated $3,386,145
- MARSHALL WACE, LLP removed 1,151,846 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,891,133
- MILLENNIUM MANAGEMENT LLC added 1,049,900 shares (+4162.0%) to their portfolio in Q1 2025, for an estimated $2,635,249
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ABSI Analyst Ratings
Wall Street analysts have issued reports on $ABSI in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 07/28/2025
- Needham issued a "Buy" rating on 05/14/2025
- Keybanc issued a "Overweight" rating on 04/16/2025
- Guggenheim issued a "Buy" rating on 03/20/2025
- HC Wainwright & Co. issued a "Buy" rating on 03/19/2025
To track analyst ratings and price targets for $ABSI, check out Quiver Quantitative's $ABSI forecast page.
$ABSI Price Targets
Multiple analysts have issued price targets for $ABSI recently. We have seen 5 analysts offer price targets for $ABSI in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Vikram Purohit from Morgan Stanley set a target price of $6.4 on 07/28/2025
- Gil Blum from Needham set a target price of $9.0 on 05/14/2025
- Scott Schoenhaus from Keybanc set a target price of $9.0 on 04/16/2025
- Vamil Divan from Guggenheim set a target price of $10.0 on 03/20/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $7.0 on 03/19/2025
Full Release
VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report business updates and financial and operating results for the second quarter 2025 after market close on Tuesday, August 12, 2025.
Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.
Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn ( @absci ), X ( @Abscibio ) and YouTube .
Investor Contact
Alex Khan
VP, Finance & Investor Relations
[email protected]
Media Contact
[email protected]
